1 / 22

Lupin Ltd

Lupin Ltd. Quarter 3 Investor Presentation. Corporate Highlights – Q3 10-11. 19 consecutive quarters of growth in sales and profits Net sales grew by 17% to Rs. 14,672 million during Q3, FY 2010-11, up from Rs. 12,554 million (Q3 FY 09-10)

denim
Télécharger la présentation

Lupin Ltd

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Lupin Ltd Quarter 3 Investor Presentation

  2. Corporate Highlights – Q3 10-11 • 19 consecutive quarters of growth in sales and profits • Net sales grew by 17% to Rs. 14,672 million during Q3, FY 2010-11, up from Rs. 12,554 million (Q3 FY 09-10) • Net profits grew by 39% to Rs. 2,240 million during Q3, FY 2010-11, as compared to Rs 1,606 Mn. (Q3 FY 09-10) • Growth across all geographies • US business grew by 15% in USD terms • Japan grew by 12% in JPY terms • S African business grew at 37% in ZAR terms • India Region sales continued to grow at 16% • Capex spend at Rs 107 Crores to meet expected demand. • Revenue Expenditure on R&D increased by 0.5% to Rs. 1178 Mn., amounting to 8% of Net Sales during Q3, FY 2010-11, as against Rs. 939 Mn., 7.5% of Net Sales (Q3, FY 2009-10) • During the quarter the company filed 5 ANDA’s bringing the Cumulative filings as of Q3, FY 2010-11, to 137 filings, of which 47 have been approved by the US FDA • Strategic alliance with Farmanguinhos and Department of Health, Brazil. • Settled litigations with Sunovion over Generic of Lunesta

  3. Financial Trend YTD December 2010-11…. Sales +21% EBIDTA +27% PAT +38%

  4. Financial Trend Q3 2010-11…. Sales +17% EBIDTA +15% PAT +39% All figures are in Mn

  5. Financial Highlights : Q3 10-11

  6. Balance Sheet Ratios Rs Mn

  7. Business Break up Revenue Mix : Q3 10-11 Geographical Break up FD Sales

  8. Corporate Highlights FY 09-10 • 15 consecutive quarters of growth in sales and profits • Growth across all geographies • US business grew by 28% in dollar terms • Japan grew by 10% in JPY terms • S African business grew at 34% in ZAR terms • India Region sales continued growth rate at 18% • Capex spend at Rs 443 Crores to meet expected demand • Year of strong research delivery • 37 ANDAs and 19 DMFs filed in the year • IP settlements – Lotrel (Benazepril/Amlodipine), Namenda (Memantine) • Licensing of Rifaximin ER to Salix for the US • Year of Regulatory compliance • Mandideep facility cleared of Warning Letter in 7.5 months • All plants inspected by FDA

  9. Financial Trend 09-10….. Sales +25% EBIDTA +34% PAT +36% CAGR 45% CAGR 49% CAGR29% All figures are in Mn

  10. Business Update

  11. Advanced Markets – US and Europe USD 000 • Generics – EU • Recorded impressive growth of 72% during the quarter. • Launched Trimetazidine, where Lupin was the first to get approval • Launched Clarithromycin XL in France during the quarter • Cefpodoxime Proxetil tabs France – 72% market share • Ceftiofur – Ranked #1 generic • Branded • Branded portfolio forms 29% of US Turnover • Generics – US • Settled ongoing litigations with Sunovion over Generic of Lunesta. • 5th largest Generic player in the U.S. in terms of prescriptions (IMS Health) • Generics business grew by 49% • No. 1 in 13 out of 29 products marketed • Top 3 in 28 of the 29 products

  12. Rs Mn India Region Formulations • Aggressive focus on brand building • Extensive collaboration with thought leading institutions • Continues to be among the fastest growing pharma company in the domestic space @ 16% • Contributed 27% to Lupin’s overall revenues during Q3, FY 2010-11 • Branded business grew by 14% • Current Field Force strength at 4183 • 6 products find a place among the top 300 in the industry • 11 new products launched in the Quarter

  13. JPY Mn Japan • Profit enhancement measures to yield greater results in the days to come • Registered Net Sales of Rs. 1727 Mn and contributed 12% to Lupin’s consolidated revenues during the quarter • Identified 4 products for manufacturing shift to Goa plant • Launched 5 new products till date, namely Latanoprost ED Fluvoxamine , Rabeprazole, Omeprazole Inj and Glimeperide • Market leader in Risperidone in terms of units • Significant player in Amlodipine

  14. ZAR Mn South Africa • Sixth largest generic company in the S African market • Leading presence in CVS • Several new products under registration • Future growth through improved generics, IP challenges and in-licensing • Growth sustained at over 37% in ZAR terms • Leaders in Amlodipine and Bilocor in unit sales

  15. ROW • New brand launches in Philippines • Women’s health, primary care and pediatric segments • Brand acquisition and in-licensing – a common theme across markets • OTC promotion support in mass media • Created thrust in three countries across CIS – Russia, Ukraine and Kazakhstan • Strategic focus on tender / hospital business paying rich dividends in CIS • Increased focus on brand building and entry into retail chains

  16. API and Intermediates • Cost, quality and reliability are the cornerstones of our API strategy • Global leadership in chosen therapies • Cephs • Ceph-intermediates • Anti-TB range • Lisinopril • India’s most profitable API entity – ROCE 36% • Achieved global cost, capacity and marketshare leadership in most products • Strategic input into formulations business

  17. Research and Development • Talent pool of 700+ scientists • 137 ANDAs, 105 DMFs • Litigation Settlements – Loestrin Fe, Femcon Fe. • Ability to churn out rich pipeline across geographies • Increased focus on F2F and Para IV’s • Strength in drug delivery • Bioadhesive • Laser-drilled • Matrix/coated • Taste-masking • Revamping Drug Discovery • Requisite infrastructure in place • Total expenditure Q3 2010-11 – Rs. 1,178 Mn, 8% of Net sales

  18. US Generics Pipeline • 137 products filed, 47 approved • Para IV’s addressing market size of US$ 30 Bn • F2Fs – Desloratadine, Memantine, Duloxetine, Eszopiclone, Ziprasidone, Lanthanum Carbonate, Pregabalin, Lo-Seasonique, Seasonale • Exclusive F2Fs – Fortamet, Glumetza, Cipro DS • Differentiated products • Oral contraceptives • Ophthalmic • Niche products – Niacin XR, Esomeprazole, Tricor, Sevelamer

  19. The Way Ahead

  20. Lupin’s Core Strength in Generics Managing the Environment Advantage • Local market knowledge • Speed & agility • High quality products • Low cost manufacturing

  21. Focal Points Increase Market Share Increase Margins

  22. Thank You

More Related